Moderated Poster Session IV: General/Endourology/Stones

摘要

Background: The influence of financial ties to pharmaceutical companiesremains controversial. We aimed to assess a potential relationshipbetween pharmaceutical payments and prescription patterns for degarelixand denosumab.Methods: Medicare Provider Utilization and Payment Data: Physician andOther Supplier Public Use File (Medicare B) data containing 2012 claimscompared to OpenPayments (Sunshine Act) data for the second half of2013. Urologists and medical oncologists who billed Medicare for degarelixor denosumab were cross-referenced in both databases and payments wereaggregated into a consolidated dataset. Adjusted beneficiary count and totalMedicare reimbursement were compared according to receipt of Sunshinepayment, and an association between Sunshine payment amount and totalMedicare reimbursement was also assessed.